Drug treatment associated with a significant reduction in death risk following opioid overdose
1. Buprenorphine and methadone maintenance treatment (MMT) was associated with reduced death in opioid users.
2. No significant associations were found between naltrexone and all-cause mortality or opioid-related mortality.
Study Rundown: Opioid overdose has become a rising problem in North America. There are several medications currently available to help reduce death from opioid overdose, including buprenorphine, MMT and naltrexone. The authors of this study aimed to evaluate the relationship between all-cause and opioid-related mortality with the use of medications for opioid use disorder (MOUD) administered after overdose. In general, it was observed that buprenorphine and MMT were associated with a reduction in both all-cause and opioid-related mortality, while no associations were observed with naltrexone. This study had several limitations. First, the findings from this study may not be generalizable to all populations, as it was only conducted in Massachusetts. Further, the data was subject to selection bias.
Relevant Reading: Treatment of opioid dependence with buprenorphine: current update
In-Depth [retrospective cohort]: The authors conducted a retrospective cohort study in order to assess MOUD following opioid overdose. A total of 17 568 patients with opioid overdose from Massachusetts were included in this study. The three types of MOUD that were evaluated were MMT, buprenorphine, and naltrexone. Data was analyzed using a multivariable Cox proportional hazards model. In general, 30% of patients received any form of MOUD during the 12 months of the study, with 13% receiving buprenorphine (n = 2228) and 8% receiving MMT (1416). Out of the patient cohort, the all-cause mortality was 4.7 deaths (95% CI, 4.4 to 5.0 deaths) per 100 person years. Opioid-related mortality was 2.1 deaths (CI, 1.9 to 2.4 deaths) per 100 person-years. There was a reduction in both all-cause and opioid-related mortality for buprenorphine (AHR, 0.63 [CI, 0.46 to 0.87] and AHR, 0.62 [CI, 0.41 to 0.92]) as well as MMT (AHR 0.47 [CI, 0.32 to 0.71] and AHR, 0.41 [CI, 0.24 to 0.70]).
©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Practical Tips to Improve HIV/AIDS Medication Adherence
- Threat of Zika Virus Still Significant in California
- Penicillin Allergies: Commonly Reported but Rarely Accurate
- Physical Activity Associated With Cognitive Benefits in Women Living With HIV
- Improved Immune Response to Pneumococcal Vaccine in ANCA-Associated Vasculitis
- Evaluation of Appropriateness of Ceftriaxone Use in the Emergency Department
- Risk Factors for Prosthetic Joint Infection Increase Likelihood for Surgical Revision
- CDC: Increase in Rate of STDs for Fourth Consecutive Year in the United States
- Effect of Respiratory Tract Microbiome on Susceptibility to Viral Infections
- Gram-Negative Bacteria Antibiotic Susceptibility for Pneumonia in the ICU
- Detectable HCV RNA at End of Treatment May Not Influence SVR Rates
- New Q Fever Foci Identified, Including Acute Endocarditis, Lymphadenitis
- HIV Medical Providers Have Gaps in Understanding the Affordable Care Act
- Metabolic Effects of Initiating Lopinavir/Ritonavir Treatment in Children
- CDC Syphilis Summit: Issues in Diagnosis and Management